Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This trial is testing a drug called CX-5461, which targets the machinery that cancer cells use to make proteins, in patients whose tumors have DNA repair defects (such as BRCA1/2 or PALB2 mutations). These defects make cancer cells more vulnerable to this type of drug. **You may be eligible if...** - You are 18 or older with cancer of the pancreas, prostate, breast, or ovary (main cohort), or ovarian/fallopian tube/peritoneal cancer (exploratory cohort) - Your tumor has a documented mutation in a DNA repair gene such as BRCA1, BRCA2, PALB2, ATM, CHEK2, or others on the approved list - Your disease has measurably progressed recently - You have adequate blood counts and organ function - You are willing to undergo tumor biopsies before and during treatment **You may NOT be eligible if...** - You have a known photosensitivity condition (you must agree to strict sun protection) - You are pregnant or breastfeeding - You have active brain metastases or bowel obstruction - You have a known heart rhythm abnormality (prolonged QT interval) - You have active eye surface disease or a history of certain eye conditions - You have had recent major surgery or are on strong CYP3A4 inhibitors Talk to your doctor to see if this trial is right for you.